WFRF:(Kmezic S)
Sökning: WFRF:(Kmezic S) > Efficacy and Safety...
- 5 av 5
- Föregående post
- Nästa post
- Till träfflistan
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis The RINOMAX Randomized Clinical Trial
-
- Piehl, F. (författare)
- Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden.;Karolinska Inst, Ctr Mol Med, Neuroimmunol Unit, L8 04, S-17176 Stockholm, Sweden.;Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
-
- Eriksson-Dufva, A. (författare)
- Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden.;Karolinska Inst, Ctr Mol Med, Neuroimmunol Unit, L8 04, S-17176 Stockholm, Sweden.;Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
-
- Budzianowska, A. (författare)
- Ryhov Reg Hosp, Dept Neurol & Rehabil, Jönköping, Sweden.
- visa fler...
- visa färre...
- Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden;Karolinska Inst, Ctr Mol Med, Neuroimmunol Unit, L8 04, S-17176 Stockholm, Sweden.;Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden. Ryhov Reg Hosp, Dept Neurol & Rehabil, Jönköping, Sweden. (creator_code:org_t)
- American Medical Association (AMA), 2022
- 2022
- Engelska.
- Ingår i: Jama Neurology. - : American Medical Association (AMA). - 2168-6149 .- 2168-6157.
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- IMPORTANCE Rituximab is a third-line option for refractory generalized myasthenia gravis (MG) based on empirical evidence, but its effect in new-onset disease is unknown. OBJECTIVE To investigate the efficacy and safety of rituximab compared with placebo as an add-on to standard of care for MG. DESIGN, SETTING, AND PARTICIPANTS This randomized, double-blind, placebo-controlled study took place throughout 48 weeks at 7 regional clinics in Sweden. Key inclusion criteria were age older than 18 years, onset of generalized symptoms within 12 months or less, and a Quantitative Myasthenia Gravis (QMG) score of 6 or more. Patients were screened from October 20, 2016, to March 2, 2020. Key exclusion criteria included pure ocular MG, suspected thymoma, previous thymectomy, and prior noncorticosteroid immunosuppressants or high doses of corticosteroids. INTERVENTIONS Participants were randomized 1:1 without stratification to a single intravenous infusion of 500 mg of rituximab or matching placebo. MAIN OUTCOMES AND MEASURES Minimal disease manifestations at 16 weeks defined as a QMG score of 4 or less with prednisolone, 10 mg or less daily, and no rescue treatment. RESULTS Of 87 potentially eligible patients, 25 were randomized to rituximab (mean [SD] age, 67.4 [13.4] years; 7 [28%] female) and 22 to placebo (mean [SD] age, 58 [18.6] years; 7 [32%] female). Compared with placebo, a greater proportion with rituximab met the primary end point; 71% (17 of 24) in the rituximab group vs 29% (6 of 21) in the placebo group (Fisher exact test P = .007; probability ratio, 2.48 [95% CI, 1.20-5.11]). Secondary end points, comparing changes in Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life at 16 weeks with QMG at 24 weeks did not differ between groups with censoring for rescue treatment (per-protocol analysis) but were in favor of active treatment when rescue treatment was taken into account by worst rank imputation (post hoc analysis). Rescue treatments were also more frequent in the placebo arm (rituximab: 1 [4%]; placebo, 8 [36%]). One patient in the placebo arm had a myocardial infarction with cardiac arrest and 1 patient in the active arm experienced a fatal cardiac event. CONCLUSIONS AND RELEVANCE A single dose of 500 mg of rituximab was associated with greater probability of minimal MG manifestations and reduced need of rescue medications compared with placebo. Further studies are needed to address long-term benefit-risk balance with this treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- double-blind
- mycophenolate-mofetil
- Neurosciences & Neurology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- 5 av 5
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Piehl, F.
- Eriksson-Dufva, ...
- Budzianowska, A.
- Feresiadou, Amal ...
- Hansson, William
- Hietala, M. A.
- visa fler...
- Håkansson, Irene
- Johansson, R.
- Jons, Daniel, 19 ...
- Kmezic, I.
- Lindberg, Christ ...
- Lind, Jonas
- Lundin, Fredrik
- Nygren, Ingela
- Rostedt Punga, A ...
- Press, R.
- Samuelsson, K.
- Sundström, Peter
- Wickberg, O.
- Brauner, S.
- Frisell, T.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Medicinska och f ...
- och Neurovetenskaper
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Neurologi
- Artiklar i publikationen
- Jama Neurology
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
